He was one of the early members of the Society for Clinical Trials and active in its affairs for more than a decade.
As Director of the Bureau of Drugs (now called the Center for Drug Evaluation and Research), he presided over the transformation of the Bureau from a scientifically marginal enterprise to an organization on its way to becoming a leader in statistics and clinical trials. He was directly involved in crafting regulations for how clinical trials should be designed, how the results should be reported to the FDA, and how the results for approved drugs should be communicated to physicians and consumers. The leadership he provided during his years at the FDA established the rigorous standards for regulatory drug approval.
He brought the assumptions of a scientist to bear on the world of regulation. The country and the world have never been the same.